Stem Cell Business News keeps you updated on stem cell company news AND each issue takes a close look at public stem cell company financial statements and other documents to find out what’s really happening: beneath the surface … behind the headlines and the press releases.

The only independent biweekly report that covers stem cell companies in depth -- including including public company SEC 10-K and 10-Q analysis, IPO plans, research and clinical trial news, finance and funding, mergers and acquisitions, etc.

You'll make wiser, better informed investment decisions by having at your fingertips detailed information on products in development, preclinical and clinical trials, financial problems, merger and acquisition activity, research and marketing collaborations, significant risks, management changes, etc.

We do not forecast the market. We do not recommend buys, sells, or holds. We simply read, interview, analyze, and report, so that potential investors can make intelligent, and hopefully profitable, decisions about their stem cell company portfolio. Available in PDF format only.

View a sample issue: Click here. NOTE: To view this PDF file you will need Adobe Acrobat Reader. To download and install this free view software, click on the Adobe icon.

Subscription options:

• For-profit rate: $295.00. PDF via e-mail. This is the basic rate for public and private companies. To subscribe, click here.
   
• Nonprofit rate: $219.00. PDF. Special rate for schools, hospitals, government agencies, nonprofit organizations, etc. To subscribe, click here.
   
• Individual rate: $119.00. PDF. For students, patients, and patients' families. To subscribe, click here.
  
  With any subscription level, your first month is FREE!

Subscribe to both Stem Cell Research News AND Stem Cell Business News at the same time at the corporate rate! Save $100 on both subscriptions together. Click here to order.